loader

RenovoRx Inc.

NASDAQ:RNXT
1 min read

RenovoRx to Host Third Quarter 2025 Financial Results and Business Highlights Conference Call on November 13th at 4:30 p.m. ET

RenovoRx Expands Scientific Advisory Board with Internationally Renowned Interventional Oncologist, Thierry de Baère, MD, PhD

RenovoRx's PanTheR Post-Marketing Registry Study Progresses with First Clinical Procedure and Addition of Two Participating Clinical Sites

RenovoRx CEO Shaun Bagai to Present at iAccess Alpha Virtual Best Ideas Fall Investment Conference 2025 on September 16th

RenovoRx CEO Shaun Bagai to Present at H.C. Wainwright's 27th Annual Global Investment Conference in New York City, September 8-10, 2025

RenovoRx Reports Commercial Revenue Growth in the Second Quarter 2025 and Announces Positive Independent Data Monitoring Committee Recommendation to Continue Pivotal Phase III TIGeR-PaC Trial Based on Interim Data Review

RenovoRx Inc is a clinical-stage biopharmaceutical company. It is focused on developing therapies for the local treatment of solid tumors and conducting a Phase 3 registrational trial for lead product candidate RenovoGem.

Latest News

More News

Latest News

Outlook Reports world

Resource
Tech
Life Science

Browse Companies

Resource
Tech
Life Science
MARKETS
COMMODITIES
CURRENCIES